"Investigación médica: Houston tenemos un
problema".
Dirigido por AlvaroToepke, analiza el modelo actual de
investigación médica y su impacto en la salud. Esta iniciativa surge con el
objetivo de sensibilizar y movilizar a la sociedad para resolver una realidad
que nos afecta a todos.
Bajo el lema de "el documental que no quieren que
veas", en él expertos y líderes de opinión de todo el mundo aportan datos
tan contundes como escalofriantes sobre el obsoleto modelo de investigación y
desarrollo de fármacos, que afecta directamente a la salud de todos.
Porque en este documental expertos y líderes de opinión de
todo el mundo aportan datos tan contundes como escalofriantes sobre el perverso
modelo de investigación médica.
Porque la verdad incomoda a los que tratan de
ocultarla. Porque la información es poder y
porque cuantos más sepamos lo que
está pasando, más podremos hacer por cambiar la situación.
Por este motivo creemos que es importante que lo veas y
saques tus propias conclusiones. (Más)
Shane Ellison has a masters degree in organic chemistry and is a two-time recipient of the prestigious Howard Hughes Medical Institute Research Grantfor his studies in biochemistry and physiology. Here Shane exposes the inner workings of the psycho/pharmaceutical industry, the manufacture and marketing of psychiatric drugs and the fact that the psycho/pharma industry is well aware their drugs do not cure anyone. He previously worked for bothArray BioPharma and Eli Lilly.
Evergreening refers to a variety of legal and business strategies by which technology producers with patents over products that are about to expire retain royalties from them, by either taking out new patents (for example over associated delivery systems, or new pharmaceutical mixtures), or by buying out or frustrating competitors, for longer periods of time than would normally be permissible under the law.
Evergreening is not a formal concept of patent law; it is best understood as a social idea used to refer to the myriad ways in which pharmaceutical patent owners use the law and related regulatory processes to extend their high rent-earning intellectual property rights particularly over highly profitable (either in total sales volume or price per unit) "blockbuster" drugs.
Thus, while the courts are an instrument frequently used by pharmaceutical brand name manufacturers to prolong their patent royalties, evergreening is rarely mentioned explicitly by judges in patent protection cases. The term usually refers to threats made to competitors about a brand-name manufacturer's tactical use of pharmaceutical patents (including over uses, delivery systems and even packaging), not to extension of any particular patent over an active product ingredient. (Más)
The most
daunting challenge facing the approved drugs—not to mention hundreds of
pipeline agents targeting other inhibitory pathways, plus upcoming disparate
but equally promising modalities, like vaccines—is monetary. Even before new
immunotherapies arrived, oncology was undergoing breathtaking growth. Between
2003 and 2013, global spending on cancer doubled. Expenditures on oncology
medicines grew by 10% in 2014, reaching $100 billion, up from $75 billion just
five years earlier.
More sobering, growth has thus far been driven by targeted
therapies, drugs like Novartis’s Gleevec. The industry has not yet begun to
feel the full impact of immunotherapy, where a CTLA-4 combined with Opdivo
retails for $270,000 annually—price tags that promise to redefine the word
“unsustainable.”
On their own, anti-PD1 therapies Keytruda and Opdivo sell for
around $150,000 a year. Another recent example includes Pfizer’s Ibrance
(palbociclib), approved in February 2015 and priced at about $120,000 a year.
Some of the
best-known over- the-counter medicines are no better than traditional home-made
remedies, doctors have warned.
They say
shoppers are spending a staggering £2.5 billion a year on expensive branded
pills and lotions when cheaper, generic versions are just as effective.
One of the
biggest money-spinners is Britain’s £350 million market in ‘targeted’
painkillers, which claim to treat specific areas of the body, such as the back.
But there
is no evidence these cleverly marketed painkillers can focus on a particular
area, according to Dr ChrisVan Tulleken, a microbiologist who has investigated
the effectiveness of over-the-counter medicines. In fact, he says, unbranded
equivalents work just as well.
Scientists
have also cast doubt on the effectiveness of heating or cooling rubs and sprays
for muscle strains – a market worth £87 million in Britain. Many of the branded
products use emotive language such as ‘deep heat’ or ‘penetrating’, but sport
scientists have questioned the honesty of these descriptions.
Further
queries have been raised about how effective over-the- counter cough medicines
are and whether they are worth the £100 million a year spent on them.
Several
experts warn many cough syrups are no better than home-made honey-and-lemon
drinks. Meanwhile, doctors say people are often better off taking individual
drugs – such as paracetamol for pain,
ibuprofen for muscle inflammation and decongestants for a blocked nose – rather
than all-in-one remedies which can contain several different drugs.
Dr VanTulleken tested popular over-the-counter pharmaceuticals in the BBC programme
The Truth About Your Medicine Cabinet and concluded ‘most of the products we
buy are unnecessary’. He said: ‘If they stopped selling this stuff tomorrow
nothing bad would happen. None of it is keeping us alive. It doesn’t do us much
good.’
But he
stressed that over-the-counter medicines are not completely useless and that
some worked very effectively. Even those that had no real physical benefit had
a ‘real placebo effect’ that does make people feel better.
The
Proprietary Association of Great Britain, the trade association representing
manufacturers of branded over-the-counter medicines, said all claims made on
the packaging of remedies and drugs sold in pharmacies was approved by the
Medicines and Healthcare Products Regulatory Agency. (Ver)
As the sun rose on the first day of the Eid holiday, Youssef, an apprentice in a Cairo butcher shop, sat, knife in hand, covered in blood, nodding off. He had been awake for more than 24 hours, chopping up cows, goats and sheep in preparation for the holiday feast.
From the rowdy crowd of customers and bleating animals, another blood-covered butcher appeared with a packet of medication in hand. He popped a small red pill into Youssef's palm, and the apprentice took it immediately.
In minutes, Youssef - who declined to give his last name - was up, energised and back to work.
The pill was tramadol, an opiate that increases brain serotonin levels and relieves pain. This prescription-only painkiller is not as strong as heroin, but it shares many of the same effects. Although it is an opiate, it also has some anti-depressant properties, which make users feel more energetic.
Egyptians are using the pill as a recreational drug and also, reportedly, as an aphrodisiac. But most commonly, it serves as a cheap energy boost. At $3 for a sheet of ten pills, tramadol is generally affordable even in Egypt's dismal economy, and for many working-class people it has become a solution for the long, arduous workdays. A small-time Cairo drug dealer, who asked to be identified by the pseudonym *Mohamed Farafiro, claimed that Egyptians like using the drug because it makes them productive.
Tramadol was first introduced to Egypt as a medication for cancer patients, and was produced in Germany and local pharmaceutical plants. Egyptians started experimenting with the pill roughly ten years ago, according to drug dealers, casual users, and the United Nations Office on Drugs and Crime.
Soon it caught on, and those who were taking tramadol to relax began to use it during work. Its popularity grew when the floundering job market forced many educated Egyptians into trade work and manual labour. "Lots of people take tramadol because they have two jobs and they can hardly sleep," said Ahmed Tourk, from the working-class Cairo neighborhood of Shubra. (Más)
GlobaLeaks is an open source project aimed at creating a worldwide, anonymous, censorship-resistant, distributed whistleblowing platform.
Why is transparency important?
GlobaLeaks strives to increase accountability and transparency in our society. When information that affects the public remains hidden, democracy and economies cease to function properly.
Start a GlobaLeaks node, demand transparency!
We believe the public should demand that governments and companies be more accountable for their actions. And we believe governments and economies that embrace openness will benefit by promoting trust and enabling informed discourse and decision-making.
For more details on running your own globaleaks node see the Globaleaks Installation Guide.
Este sitio web cumple con las leyes vigentes en el país en cuanto a tratamiento
de datos personale y está de acuerdo a la "Ley Orgánica 15/1999, de 13
de diciembre, de Protección de Datos de Carácter Personal", disponible en
http://www.boe.es/buscar/doc.php?coleccion=iberlex&id=1999/23750
La información confidencial, privada o semi-privada de los usuarios: direcciones de correo electrónico, contenidos de correos electrónicos, dirección IP, etc. Es tratada de acuerdo a estos criterios y no es cedida ni vendida a terceros. Siendo el editor del blog el responsable del tratamiento de los datos y el cumplimiento de las normas. Los usuarios tienen derecho de acceso, rectificación y cancelación de sus datos.
El sitio web NO utiliza cookies
El sitio web no solicita o comparte ningún tipo de información con los usuarios.
"Este sitio web utiliza Google Analytics para analizar las visitas al sitio web y así mejorar sus contenidos. Para más información sobre la política de privacidad de Google Analytics, visite el siguiente enlace:
https://support.google.com/analytics/answer/6004245?hl=es
Los usuarios puedan solicitar información adicional a
pharmacoserias@gmail.com
PHARMACOSERÍAS es mantenido exclusivamente con propios fondos personales del editor
La parte interactiva se rige de acuerdo a
http://www.hon.ch/cgi-bin/HONcode/guidelines_comments_en.pl
El blog está moderado POR SU EDITOR, Fernando Comas Vega, comunicador en salud con revisiones semanales.
http://www.hon.ch/HONcode/Webmasters/Guidelines/hc_p1_sp.html
"Cada usuario proporcioná referencias y/o enlaces que justifiquen sus afirmaciones sobre medicina y salud, siempre que no se trate de una experiencia personal vivida por él mismo".
"Usuarios y moderadores se comprometen a publicar información de cuya exactitud y veracidad tengan constancia".
La actividad del moderador es de carácter voluntario, no retribuida y no existen conflictos de intereses.
No se permite a los usuarios de la plataforma publicar mensajes con contenido publicitario.
Este blog es moderado por su Editor, Fernando Comas Todos los usuarios de la plataforma no deben ser considerados como profesionales de salud. Es un blog de información sobre Marketing farmacéutico y hechos relacionados.
Este blog está dirigido a toda persona que tenga relación directa o interés con el mundo de la industria farmacéutica.
Este blog no está financiado por ningún patrocinador. Tan solo recibe los anuncios Google(claramente identificados) y estos no implican ningún condicionamiento respecto a su línea editorial.
Este blog tiene un carácter meramente informativo. La información y los comentarios que se reflejan aquí no deben entenderse como consejo médico. Consulte siempre a un especialista ante cualquier duda sobre su salud o la de sus familiares. El administrador y/o creadores de este blog no se hacen responsables sobre el uso que se haga de esta información.
_______________________________________
Comentarios:
1) Es necesario indicar datos personales para publicar
comentarios
2) Los mensajes publicados pueden
ser leídos y, en consecuencia, usados por cualquier lector.
3) La plataforma Web 2.0 permite a los
usuarios cancelar o modificar sus propios mensajes, si se solicita al Editor.
DECLARACION DE PRINCIPIOS: Information provided on the site is meant to complement and not replace any advice or information from a health professional is clearly provided. (Last modification feb 26, 2010)
LA VERDAD ACERCA DE LA INDUSTRIA FARMACEUTICA Marcia Angell Editorial Norma 2006 (Si eres capaz de leer en inglés...huye y busca el original. La traducción es de "Juzgado de Guardia"
TRUTH ABOUT THE DRUG COMPANIES: How They Deceive Us and What to Do About Marcia Angell Random House Pub., 2004
LA PILDORA DE LOS 800 MILLONES DE DOLARES Merrilll Goozner EDITORIAL NORMA 2004
EL GRAN SECRETO DE LA INDUSTRIA FARMACEUTICA Philippe Pignarre Ed. Gedisa 2005
LOS INVENTORES DE ENFERMEDADES Jörg Blech Ediciones Destino imago mundi 2005
Entradas
